Aura Biosciences (NASDAQ:AURA – Get Rating) released its quarterly earnings data on Wednesday. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.06, Yahoo Finance reports.
Aura Biosciences Stock Up 0.3 %
AURA stock opened at $10.21 on Friday. Aura Biosciences has a fifty-two week low of $9.43 and a fifty-two week high of $24.83. The firm’s 50-day simple moving average is $10.55 and its 200 day simple moving average is $12.30.
Wall Street Analyst Weigh In
Separately, JMP Securities dropped their price objective on shares of Aura Biosciences from $30.00 to $25.00 and set an “outperform” rating on the stock in a report on Thursday.
Insider Buying and Selling
Hedge Funds Weigh In On Aura Biosciences
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Morgan Stanley grew its position in Aura Biosciences by 17.1% in the 4th quarter. Morgan Stanley now owns 64,603 shares of the company’s stock valued at $678,000 after buying an additional 9,451 shares in the last quarter. Alps Advisors Inc. bought a new position in shares of Aura Biosciences during the 4th quarter valued at about $257,000. Alyeska Investment Group L.P. bought a new position in shares of Aura Biosciences during the 4th quarter valued at about $225,000. Price T Rowe Associates Inc. MD bought a new position in shares of Aura Biosciences during the 4th quarter valued at about $7,762,000. Finally, Renaissance Technologies LLC bought a new position in shares of Aura Biosciences during the 4th quarter valued at about $138,000. Institutional investors own 55.63% of the company’s stock.
Aura Biosciences Company Profile
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
- PacWest Bancorp May Escape a Credit Downgrade After this Happens
- Dollar General Offers Great Prices, but the Stock isn’t a Value
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.